The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) and (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.

##STR00001##

Disclosed are a salt represented by formula (I), an acid generator, and a resist composition:

##STR00001##

wherein R.sup.1, R.sup.2 and R.sup.3 each represent a hydroxy group, *—O—R.sup.10, *—O-L.sup.10-CO—O—R.sup.10, etc.; L.sup.10 represents an alkanediyl group; R.sup.10 represents an acid-labile group; R.sup.4 to R.sup.9 each represent a halogen atom, a haloalkyl group, etc.; A.sup.1, A.sup.2 and A.sup.3 each represent a hydrocarbon group, etc.; m1 and m7 represent an integer of 0 to 5, m2 to m6, m8 and m9 represent an integer of 0 to 4, 0≤m1+m7≤5, 0≤m2+m8≤4, 0≤m3+m9≤4, and at least one of m1, m2 and m3 represents an integer of 1 or more; X.sup.4 represents a single bond, —CH.sub.2—, etc.; and Al.sup.− represents an organic anion.

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

This invention provides for compounds of the formula: ##STR00001##
wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

This invention provides for compounds of the formula:

##STR00001##

wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

The present invention relates to a process to produce compounds of the formula (1) which are suitable for use in electronic devices, as well as to intermediate compounds of formula (Int-1) and compounds of formula (1-1) and (1-2) obtained via the process. These compounds are particularly suitable for use organic electroluminescent devices. The present invention also relate to electronic devices, which comprise these compounds.

The present invention relates to a process to produce compounds of the formula (1) which are suitable for use in electronic devices, as well as to intermediate compounds of formula (Int-1) and compounds of formula (1-1) and (1-2) obtained via the process. These compounds are particularly suitable for use organic electroluminescent devices. The present invention also relate to electronic devices, which comprise these compounds.

The present invention relates to a compound of the general formula I and the pharmaceutically acceptable salts thereof; where the variables are as defined in the claims and the description. The invention also relates to the compounds of formula I for use in the treatment or prophylaxis of muscle wasting conditions, of skeletal or cardial muscle atrophy, of conditions, in particular of myopathies, which are associated with an increased Muscle RING Finger 1 (MuRF1) expression and of other conditions; to the compounds of formula I for use as a medicament; to a pharmaceutical composition comprising at least one compound of formula I and to a method for treating said conditions.

##STR00001##

The present invention relates to a compound of the general formula I and the pharmaceutically acceptable salts thereof; where the variables are as defined in the claims and the description. The invention also relates to the compounds of formula I for use in the treatment or prophylaxis of muscle wasting conditions, of skeletal or cardial muscle atrophy, of conditions, in particular of myopathies, which are associated with an increased Muscle RING Finger 1 (MuRF1) expression and of other conditions; to the compounds of formula I for use as a medicament; to a pharmaceutical composition comprising at least one compound of formula I and to a method for treating said conditions.

##STR00001##